First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Commentary|Articles|October 14, 2026
Long-Term and Novel ADC Data Dominate Top Gynecologic Cancer Abstracts at ESMO 2026
Author(s)Riley Kandel
Fact checked by: Chris Ryan
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
Advertisement
Advertisement
As anticipation builds for the
Related to this article
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
A patient treated at the highest dose level of lira-cel to date had stable disease 90 days after infusion in a phase 1 trial in recurrent ovarian cancer.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
Advertisement
Advertisement